Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,500 shares, a ...

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System AtrophyMASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy ...

Japanese drugmaker Chugai, which is majority owned by Roche, On Friday revealed that Zenyaku Kogyo has obtained regulatory ...

Researchers have developed a new optical biosensor to detect the monkeypox virus. The biosensor can provide results in 20 minutes. The new technology ...

mAbs 2014; 6 (2):523-532). Cusatuzumab is currently being evaluated in patients ... Cusatuzumab is a first-in-class high-affinity humanized monoclonal antibody targeting CD70, an immune checkpoint ...

Oppenheimer began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note issued to ...